Eli Lilly and Company $LLY Shares Acquired by E. Ohman J or Asset Management AB

Key Points

• E. Ohman J or Asset Management AB increased its Eli Lilly stake by 137.4% in the second quarter, bringing its holdings to 65,270 shares valued at approximately $78.3 million. Institutional investors collectively own 82.53% of LLY.
• Analysts maintain a positive view, with a consensus rating of “Moderate Buy” and an average price target of $1,292.18 after several firms raised their targets.
• Eli Lilly reported strong quarterly results, with revenue up 47.7% year over year to $22.97 billion and adjusted EPS of $8.38 versus the $6.40 consensus estimate. Management issued fiscal 2026 EPS guidance of $35.50-$36.50.

E. Ohman J or Asset Management AB boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 137.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,270 shares of the company's stock after acquiring an additional 37,773 shares during the period. Eli Lilly and Company accounts for about 1.8% of E. Ohman J or Asset Management AB's holdings, making the stock its 9th biggest position. E. Ohman J or Asset Management AB's holdings in Eli Lilly and Company were worth $78,287,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $30,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after purchasing an additional 24 shares during the period. New England Capital Financial Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 142.9% during the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock worth $37,000 after purchasing an additional 20 shares during the period. Finally, Maseco LLP grew its position in Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after buying an additional 28 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Citigroup boosted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Rothschild & Co Redburn lifted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Royal Bank Of Canada boosted their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 8th. Truist Financial increased their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a report on Friday. Finally, Bank of America raised their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,292.18.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Up 3.7%

Shares of LLY opened at $1,230.00 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm's 50-day moving average is $1,162.38 and its two-hundred day moving average is $1,048.95. Eli Lilly and Company has a twelve month low of $625.90 and a twelve month high of $1,249.45. The firm has a market capitalization of $1.16 trillion, a P/E ratio of 41.28, a PEG ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the prior year, the company earned $6.31 earnings per share. Eli Lilly and Company's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts predict that Eli Lilly and Company will post 36.77 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 23.22%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source